Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Telix Pharmaceuticals Ltd. (AU:TLX)
:TLX
RESEARCH TOOLSreports
Holding AU:TLX?
Track your performance easily
TLX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$10.34 - AU$27.00
Previous CloseN/A
Volume456.62K
Average Volume (3M)922.22K
Market Cap
AU$8.64B
Enterprise ValueAU$6.22B
Total Cash (Recent Filing)$2.99M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)176.3
Beta1.20
Next Earnings
Feb 19, 2025EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding334,724,500
10 Day Avg. Volume748,267
30 Day Avg. Volume922,222
Standard Deviation0.22
R-Squared0.25
Alpha0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)20.69
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit19.80
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$18.51Price Target Upside-28.26% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Telix Pharmaceuticals Ltd. News
PremiumCompany Announcements
Telix Pharmaceuticals’ Illuccix Gains European Marketing Authorization
PremiumCompany Announcements
Telix Pharmaceuticals Surpasses FY24 Revenue Expectations
PremiumCompany Announcements
Telix Pharmaceuticals Announces Proposed Securities Issue
PremiumCompany Announcements
Telix Pharmaceuticals Expands with Acquisition of Novel Biologics Platform
PremiumCompany Announcements
Telix Pharmaceuticals Expands Therapeutic Pipeline with Strategic Acquisition
PremiumCompany Announcements
Telix Pharmaceuticals Boosts CEO Remuneration Amid GrowthOptions Prices
Currently, No data available
---
Ownership Overview
6.94% Insiders
3.00% Mutual Funds
― Other Institutional Investors
86.11% Public Companies and Individual Investors
TLX FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest share price was AU$10.34 and its highest was AU$27.00 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is AU$8.64B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Feb 19, 2025 which is in 32 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Aug 22, 2024. The company reported AU$0.09 earnings per share for the quarter, missing the consensus estimate of AU$0.15 by -AU$0.06.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is 0.14.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 334,724,500 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of AU$0.09 in its last earnings report, missing expectations of AU$0.15. Following the earnings report the stock price went down -0.951%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:TLX
---
Telix Pharmaceuticals Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$18.51 (-28.26% Downside)
AU$18.51 (-28.26% Downside)
Blogger Sentiment
Bullish
AU:TLX Sentiment 70%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
131.94%
12-Months-Change
Fundamentals
Return on Equity
20.14%
Trailing 12-Months
Asset Growth
141.17%
Trailing 12-Months
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.
---
TLX Company Deck
---
TLX Earnings Call
Q2 2024
0:00 / 0:00
---
TLX Stock 12 Month Forecast
Average Price Target
AU$18.51
▼(-28.26% Downside)
Technical Analysis
CSL
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―
Race Oncology Ltd.
―
Mesoblast Limited
―
Opthea Limited
―
Best Analysts Covering TLX
1 Year
1 Year Success Rate
17/17 ratings generated profit
1 Year Average Return
+68.45%
reiterated a buy rating 5 months ago
Copying Steven Wheen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +68.45% per trade.
---